Wu Hao, Ouyang Wenbin, Deng Jing, He Yongmei, Yin Lu, Cao Xia, Chen Zhiheng, Yang Pingting, Wang Yaqin, Li Ying, Huang Xin
Department of Health Management, The Third Xiangya Hospital, Central South University, Changsha, China.
Department of Epidemiology, Hunan Normal University School of Medicine, Changsha, China.
Front Nutr. 2024 Dec 18;11:1504152. doi: 10.3389/fnut.2024.1504152. eCollection 2024.
Salt substitute is considered an effective strategy to reduce sodium and increase potassium intake and thereby lower blood pressure in China, but its benefits and risks are uncertain in real-world data. This study is designed to compare the difference in the 1-year efficacy of salt substitute and salt restriction on urinary electrolytes and blood pressure.
A total of 2,929 and 2,071 participants with the 24-h estimated urinary sodium excretion (eUNaE) above 2.36 g/d using salt substitute (SS) and salt restriction (SR) strategies, respectively, were followed for 1 year. Salt substitute users were further divided by potassium chloride (KCl) content (13% vs 25%) and duration (9-11 vs 12 months). The 24-h eUNaE and estimated urinary potassium excretion (eUKE) levels were calculated using the Kawasaki formula from spot urine sample. The SS group ( = 1,897) had lower eUNaE (3.82 ± 1.03 vs 4.05 ± 1.01 g/day, < 0.01) than the SR group ( = 1,897) after 1 year. Both 13 and 25% KCl substitutes reduced eUNaE versus restriction ( < 0.05). The SS group had a higher eUKE than the SR group (2.09 ± 0.43 vs 1.71 ± 0.62 g/day, < 0.01). The eUKE was higher with 25% versus 13% KCl substitutes, while the Na/K was lower with 25% versus 13% KCl substitutes ( < 0.05). No significant blood pressure differences occurred between the SS and SR groups ( > 0.05), whereas 25% KCl exposure was related to a lower level of SBP, regardless of whether it was compared with SR or 13% KCl.
Compared with salt restriction, salt substitute results in more sodium reduction and greater potassium increase. In spite of this, it does not result in better control of blood pressure, especially for the group receiving 13% KCl.
在中国,用低钠盐替代普通盐被认为是一种减少钠摄入、增加钾摄入从而降低血压的有效策略,但其在实际应用中的益处和风险尚不确定。本研究旨在比较低钠盐替代和限盐对尿电解质及血压的1年疗效差异。
分别采用低钠盐替代(SS)和限盐(SR)策略,对2929名和2071名24小时尿钠排泄量(eUNaE)估计值高于2.36g/d的参与者进行了为期1年的随访。低钠盐替代使用者又根据氯化钾(KCl)含量(13%与25%)和使用时长(9 - 11个月与12个月)进行了分组。采用川崎公式根据随机尿样计算24小时eUNaE和尿钾排泄量(eUKE)估计值。1年后,低钠盐替代组(n = 1897)的eUNaE低于限盐组(n = 1897)(3.82 ± 1.03 vs 4.05 ± 1.01g/天,P < 0.01)。13%和25%的KCl替代物与限盐相比,均能降低eUNaE(P < 0.05)。低钠盐替代组的eUKE高于限盐组(2.09 ± 0.43 vs 1.71 ± 0.62g/天,P < 0.01)。25% KCl替代物组的eUKE高于13% KCl替代物组,而25% KCl替代物组的钠钾比低于13% KCl替代物组(P < 0.05)。低钠盐替代组和限盐组之间血压无显著差异(P > 0.05),然而,无论与限盐组还是13% KCl替代物组相比,25% KCl替代物组的收缩压水平较低。
与限盐相比,低钠盐替代能更多地减少钠摄入并增加钾摄入。尽管如此,它并不能更好地控制血压,尤其是对于接受13% KCl的人群。